Skip to main content
. 2014 Jun 24;111(4):660–666. doi: 10.1038/bjc.2014.356

Table 2. Patient disposition.

n (%) Arm A: 840/420 mg pertuzumab, n=15 Arm B: 840 mg q3w pertuzumab, n=15
Completed six cycles of pertuzumab
14 (93.3)
11 (73.3)
Still on treatment
7 (46.7)
3 (20.0)
Discontinued treatment
8 (53.3)
12 (80.0)
 Safety
0 (0.0)
2 (13.3)
  Adverse event 0 (0.0) 1 (6.7)
  Death
0 (0.0)
1 (6.7)
 Non-safety
8 (53.3)
10 (66.7)
  Physician decision 0 (0.0) 1 (6.7)
  Progression of disease 8 (53.3) 8 (53.3)
  Withdrawal by patient 0 (0.0) 1 (6.7)